Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.
IPO Year: 1999
Exchange: NYSE
Website: agilent.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/28/2026 | $145.00 | Neutral → Buy | BofA Securities |
| 5/27/2026 | $153.00 | Outperform | RBC Capital Mkts |
| 1/20/2026 | $180.00 | Buy | HSBC Securities |
| 1/5/2026 | $160.00 | In-line → Outperform | Evercore ISI |
| 12/15/2025 | $165.00 | Equal Weight → Overweight | Barclays |
| 12/9/2025 | $170.00 | Buy | Goldman |
| 12/2/2025 | $270.00 | Overweight | Morgan Stanley |
| 10/8/2025 | $165.00 | Buy | Rothschild & Co Redburn |
| 10/8/2025 | $170.00 | Neutral → Buy | UBS |
| 2/10/2025 | $135.00 → $145.00 | Underweight → Equal Weight | Barclays |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
BofA Securities upgraded Agilent from Neutral to Buy and set a new price target of $145.00
RBC Capital Mkts initiated coverage of Agilent with a rating of Outperform and set a new price target of $153.00
HSBC Securities initiated coverage of Agilent with a rating of Buy and set a new price target of $180.00
Evercore ISI upgraded Agilent from In-line to Outperform and set a new price target of $160.00
Barclays upgraded Agilent from Equal Weight to Overweight and set a new price target of $165.00
Goldman initiated coverage of Agilent with a rating of Buy and set a new price target of $170.00
Morgan Stanley initiated coverage of Agilent with a rating of Overweight and set a new price target of $270.00
Rothschild & Co Redburn initiated coverage of Agilent with a rating of Buy and set a new price target of $165.00
UBS upgraded Agilent from Neutral to Buy and set a new price target of $170.00
Barclays upgraded Agilent from Underweight to Equal Weight and set a new price target of $145.00 from $135.00 previously
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
3 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
10-Q - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
SD - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
8-K/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
SCHEDULE 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
10-Q - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
Fastest customizable press release news feed in the world
Agilent Technologies Inc. (NYSE:A) today announced a collaboration with OpenAI and Boston Consulting Group (BCG) to accelerate the deployment of artificial intelligence (AI) across the company's products, operations, and customer workflows. "AI is a top priority, and this partnership reflects both our ambition and our execution commitment — to build the enduring capability, operating model, and capacity required to consistently deliver AI‑driven innovation value for our customers," said Padraig McDonnell, president and CEO of Agilent. "Through this collaboration with OpenAI and BCG, we are accelerating deployment of AI across our business while advancing more intelligent instruments, soft
Approval expands PD-L1 testing onto an automated workflow to support treatment decisions with KEYTRUDA® (pembrolizumab)¹,² Agilent Technologies Inc. (NYSE:A) today announced that the U.S. Food and Drug Administration (FDA) has approved the expanded use of PD-L1 IHC 22C3 pharmDx, Code GE006, for use on the Dako Omnis platform to aid in identifying patients in the United States with esophageal squamous cell carcinoma (ESCC)3, triple-negative breast cancer (TNBC)4, cervical cancer5, and gastric or gastroesophageal junction (GEJ) adenocarcinoma6, who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy. This approval expands access to PD-L1 testing across
Agilent Technologies Inc. (NYSE:A) today announced the introduction of OpenLab Sync, a new Lab Execution System (LES) that enables laboratories to digitally connect scientific workflows from method design through execution at the bench. OpenLab Sync extends Agilent's OpenLab laboratory informatics portfolio beyond traditional data and sample management, enabling guided, standardized, and traceable execution of laboratory work in regulated environments. As laboratories face increasing regulatory scrutiny, workforce turnover, and pressure to standardize operations across sites, many continue to rely on static, paper-based procedures that can introduce variability and risk. OpenLab Sync addr
Delivers strong Q2 results and raises FY26 revenue growth, margin expansion, and non-GAAP EPS(4) guidance on continued operational momentum Second-quarter fiscal year 2026 Revenue of $1.83 billion for the second quarter ended April 30, 2026, representing growth of 10.0% reported and up 6.3% core(1) compared with the second quarter of 2025. GAAP operating margin of 21.7%; non-GAAP operating margin(2) of 26.4% expanded by 130 basis points year-over-year and 180 basis points sequentially. GAAP net income of $339 million; earnings per share (EPS) of $1.20, an increase of 60% from the second quarter of 2025. Non-GAAP net income(3) of $423 million; non-GAAP EPS(3) of $1.49, an incre
Agilent Technologies Inc. (NYSE:A) today announced the release of a new multi-attribute method (MAM) workflow designed to help pharmaceutical and biopharmaceutical quality control (QC) laboratories implement liquid chromatography high-resolution mass spectrometry (LC/HRMS) in routine, regulated testing environments. The Agilent MAM solution brings together software, instrumentation, columns, consumables and standards to address practical and operational barriers that have historically limited the use of LC/HRMS in QC environments. The workflow is designed to support laboratories applying MAM to monitor critical quality attributes during late-stage development and commercial manufacturing.
New 8890B and 8860B gas chromatographs integrate intelligent monitoring and remote diagnostics Agilent Technologies Inc. (NYSE:A) today announced the launch of the new 8890B GC and 8860B GC with GC Assist. GC Assist is the new, advanced instrument intelligence that provides system monitoring, built-in troubleshooting, and remote connectivity to analytical instrumentation within the laboratory's secure network. These systems enable higher performance and productivity across gas chromatography analyses. The new systems are designed to help laboratories reduce unplanned downtime, improve data quality, and operate more efficiently by combining updated GC hardware with integrated system moni
Next-generation ICP-MS/MS delivers faster measurements, simplified workflows, and easier access to advanced elemental analysis Agilent Technologies Inc. (NYSE:A) today announced the launch of the Agilent 9500 Triple Quadrupole ICP-MS, a next-generation inductively coupled plasma mass spectrometry system designed to help single quadrupole ICP-MS laboratories more easily transition to triple quadrupole technology for advanced trace elemental analysis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522685512/en/Agilent 9500 Triple Quadrupole ICP-MS System As testing demands grow more complex and skilled resources remain limite
Agilent Technologies Inc. (NYSE:A) today announced the launch of the Agilent 1290 Infinity III Fluorescence Detector (FLD), a new fluorescence detector designed specifically for modern ultra-high-performance liquid chromatography (UHPLC) workflows. The detector extends fluorescence detection into the UHPLC era by combining ultra-trace sensitivity, UHPLC-ready chromatographic performance, and routine-ready ease of use. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521579990/en/1290 Infinity III Fluorescence Detector with front-access service design. Designed for use as a standalone detector or in-line with LC/MS systems, the
Agilent Technologies Inc. (NYSE:A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on July 22, 2026, to all shareholders of record as of the close of business on June 30, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent's board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide tru
Agilent has been awarded a contract by the Transportation Security Administration (TSA) to supply its Bulk Resolution Technology (BRT) systems to passenger security checkpoints at FIFA World Cup U.S. host city airports Agilent Technologies Inc. (NYSE:A) today announced that it has been awarded a contract by the Transportation Security Administration (TSA) and will deploy its new Bulk Alarm Resolution Technology (BRT) to security checkpoints at FIFA World Cup U.S. host city airports with the capabilities to screen larger quantities of liquids, powders, and solids commonly encountered in airport security screening operations. "Agilent is thrilled to have been selected by TSA to modernize
Live finance-specific insights
Delivers strong Q2 results and raises FY26 revenue growth, margin expansion, and non-GAAP EPS(4) guidance on continued operational momentum Second-quarter fiscal year 2026 Revenue of $1.83 billion for the second quarter ended April 30, 2026, representing growth of 10.0% reported and up 6.3% core(1) compared with the second quarter of 2025. GAAP operating margin of 21.7%; non-GAAP operating margin(2) of 26.4% expanded by 130 basis points year-over-year and 180 basis points sequentially. GAAP net income of $339 million; earnings per share (EPS) of $1.20, an increase of 60% from the second quarter of 2025. Non-GAAP net income(3) of $423 million; non-GAAP EPS(3) of $1.49, an incre
Agilent Technologies Inc. (NYSE:A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on July 22, 2026, to all shareholders of record as of the close of business on June 30, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent's board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide tru
New indices deliver transparent, comprehensive access to Australian equities for benchmarking and investment applicationsNEW YORK and SYDNEY, April 28, 2026 /PRNewswire/ -- Bloomberg today announced the launch of the new Bloomberg Australia Domestic Equity Indices. The indices are designed to provide broad and investable exposure to Australian equities for benchmarking, asset allocation, and creation of financial products for both institutional and retail investors. "The launch of our Australia Domestic Equity Indices represents a natural evolution of our offering, building on a
Agilent Technologies Inc. (NYSE:A) will release financial results for the second quarter of fiscal year 2026 after the stock market closes on Wednesday, May 27. The company will host a conference call to discuss the results at 1:30 p.m. PDT the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's Investor Relations website. A recording of the call will also be available on the website for 90 days. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's ful
Delivers solid Q1 results, raises FY26 reported revenue outlook and increases non-GAAP EPS(3) guidance while confirming core-revenue growth(1) and margin expansion First-quarter fiscal year 2026 Revenue of $1.80 billion for the first quarter ended Jan. 31, 2026, representing growth of 7.0% reported and up 4.4% on a core(1) basis compared with the first quarter of 2025. GAAP net income of $305 million; earnings per share (EPS) of $1.07, a decline of 4% from the first quarter of 2025. Non-GAAP(2) net income of $386 million; non-GAAP EPS(3) of $1.36, growing 4% from the first quarter of 2025. Fiscal year 2026 and second-quarter outlook Fiscal year 2026 revenue is expected in t
Agilent Technologies Inc. (NYSE:A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on April 22, 2026, to all shareholders of record as of the close of business on March 31, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent's board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide t
Agilent Technologies Inc. (NYSE:A) will release financial results for the first quarter of fiscal year 2026 after the stock market closes on Wednesday, Feb. 25. The company will host a conference call to discuss the results at 1:30 p.m. PST the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's Investor Relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full
Delivers solid results in Q4, initiates FY26 guidance Fourth-quarter fiscal year 2025 Revenue of $1.86 billion for the fourth quarter ended October 31, 2025, exceeding revenue guidance and representing growth of 9.4% reported and up 7.2% on a core(1) basis compared with the fourth quarter of 2024. GAAP net income of $434 million; earnings per share (EPS) of $1.53, up 25% from the fourth quarter of 2024. Non-GAAP(2) net income of $452 million; EPS of $1.59, up 9% from the fourth quarter of 2024. Full fiscal year 2025 Revenue of $6.95 billion for the fiscal year ended October 31, 2025, exceeding revenue guidance and representing growth of 6.7% on a reported basis and up 4.9% on a c
Agilent Technologies Inc. (NYSE:A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on Jan. 28, 2026, to all shareholders of record as of the close of business on Jan. 6, 2026. The timing and amounts of future dividends are subject to the determination and approval by Agilent's board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trust
Agilent Technologies Inc. (NYSE:A) will release financial results for the fourth quarter of fiscal year 2025 after the stock market closes on Monday, Nov. 24. The company will host a conference call to discuss the results at 1:30 p.m. PST the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's Investor Relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full ra
Live Leadership Updates
Agilent Technologies Inc. (NYSE:A) today announced the appointment of Michael Buckner as chief legal officer, effective today. Buckner brings nearly three decades of experience as a senior global legal executive, with a proven track record of building and leading high-performing teams and deep expertise in complex transactions and regulatory environments. "We are thrilled to welcome Michael to the Agilent team," said Padraig McDonnell, Agilent president and CEO. "His experience leading global legal organizations, combined with his expertise across governance, compliance and regulatory matters, will play a key role as we continue to advance our strategy and deliver for our customers and
Agilent Technologies Inc. (NYSE:A) will present new technologies, scientific collaborations, and integrated workflows supporting cancer research and diagnostics at the American Association for Cancer Research (AACR) Annual Meeting on April 17–22, 2026, in San Diego, California. At the meeting, Agilent will highlight advances designed to connect discovery research, translational science, and companion diagnostics development, reflecting the growing demand for more integrated approaches across the cancer research continuum. Among the technologies featured is the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation series of cell imaging and multimode micropla
Agilent Technologies Inc. (NYSE:A) today announced the appointment of Adam S. Elinoff as chief financial officer, effective Nov. 17. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027719923/en/Adam S. Elinoff, Chief Financial Officer, Agilent Technologies Elinoff brings two decades of financial experience spanning corporate finance, investor relations, strategy and business transformation, and has a proven record of driving enterprise-wide transformations, optimizing financial operations and scaling global capabilities. He joins Agilent from Amgen, a worldwide pioneer in biotechnology, where he advanced through a series of
Agilent Technologies Inc. (NYSE:A) announced today its participation at the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025 in Chicago, Illinois. Innovative Agilent products and partnerships playing a crucial role in transforming cancer research, diagnostics, and therapeutics will be featured, including: Agilent Avida DNA Cancer Panels – Based on cutting-edge next-generation sequencing (NGS) target enrichment solutions that enable simultaneous DNA and methylation profiling from a single sample, the Avida product portfolio has expanded to include three new DNA panels*. Optimized based on the requirements of the European OncNGS Consortium, these catalog p
Expands Agilent's end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing Agilent Technologies Inc. (NYSE:A) today announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722078870/en/A BIOVECTRA manufacturing facility (Photo: Business Wire) Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. The acquisition builds on Agilent's CDMO specializati
Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m
New instrument delivers the full power and capability of Agilent GCs in a compact design SANTA CLARA, Calif., May 23, 2024 /PRNewswire/ -- Agilent Technologies Inc. (NYSE:A) proudly announces the 8850 Gas Chromatograph (GC) System, a small single-channel GC that combines the legacy of the 6850 GC with the capability and system intelligence of the 8890 GC. With a focus on speed and intelligence, the 8850 GC stands poised to revolutionize labs across diverse markets, including energy, chemicals, food, and pharmaceuticals while reducing energy consumption up to 30%. Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9270251-agilent-unveils-8
New instrument delivers the full power and capability of Agilent GCs in a compact design Agilent Technologies Inc., (NYSE:A) proudly announces the 8850 Gas Chromatograph (GC) System, a small single-channel GC that combines the legacy of the 6850 GC with the capability and system intelligence of the 8890 GC. With a focus on speed and intelligence, the 8850 GC stands poised to revolutionize labs across diverse markets, including energy, chemicals, food, and pharmaceuticals, while reducing energy consumption by up to 30%. Modern labs face the seemingly contrasting goals of maximizing analytical capacity with limited bench space while reducing the overall environmental impact of their opera
Agilent Technologies Inc. (NYSE:A) today announced that Padraig McDonnell has assumed the role of Agilent CEO, effective immediately. His appointment is part of the company's CEO transition plan announced Feb. 21. McDonnell is the fourth CEO in Agilent's history and succeeds Mike McMullen, who will serve as an adviser until he retires Oct. 31. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240501393789/en/Padraig McDonnell (Photo: Business Wire) "It's an incredible honor to serve as CEO of this great company that impacts the world by advancing the quality of life," McDonnell said. "I'm proud of how we forge partnerships with our
SAN FRANCISCO, CA, June 22, 2021 (GLOBE NEWSWIRE) -- Fundbox, the financial platform for small businesses, announced today that it has appointed Hilliard Terry to its Board of Directors. Mr. Terry is an experienced executive leader, corporate board member and advisor to private equity backed portfolio companies. Mr. Terry currently serves on the board of directors of Umpqua Holdings Corporation (NASDAQ:UMPQ), a financial services company. He also serves on the board of directors of Upstart Holdings, Inc. (NASDAQ:UPST), a leading artificial intelligence consumer lending platform, and on the board of TLG Acquisition One Corporation (NYSE:TLGA), a special purpose acquisition company. "H
This live feed shows all institutional transactions in real time.
SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)